ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) and Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.
Earnings and Valuation
This table compares ENDRA Life Sciences and Bluejay Diagnostics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ENDRA Life Sciences | N/A | N/A | -$11.51 million | ($33.89) | -0.24 |
| Bluejay Diagnostics | $250,000.00 | 16.99 | -$7.72 million | ($125.15) | -0.02 |
Analyst Ratings
This is a breakdown of current ratings for ENDRA Life Sciences and Bluejay Diagnostics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ENDRA Life Sciences | 1 | 0 | 1 | 0 | 2.00 |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
ENDRA Life Sciences currently has a consensus price target of $50.00, indicating a potential upside of 515.76%. Given ENDRA Life Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics.
Profitability
This table compares ENDRA Life Sciences and Bluejay Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ENDRA Life Sciences | N/A | -194.14% | -127.89% |
| Bluejay Diagnostics | N/A | -362.07% | -299.10% |
Risk & Volatility
ENDRA Life Sciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Institutional & Insider Ownership
1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
